2m 2m 2m 2m 2m 2m 2m
BETA BIONICS (BBNX)
NASDAQ
$12.59-$0.20 (-1.60%)
Price as of Jun 03, 2026 6:22 PM EDT- $540.1MMarket Cap
- -28.79%1-Year Change
- Medical DevicesIndustry
BETA BIONICS (BBNX)
$12.59-$0.20 (-1.60%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 100.3M +53.94% | 65.1M N/A | |
Cost of Revenue | 44.7M +52.94% | 29.2M N/A | |
Gross Profit | 55.5M +54.75% | 35.9M N/A | |
Sales and Marketing Expense | 61.4M +65.57% | 37.1M N/A | |
Research and Development Expense | -34.8M +32.86% | -26.2M N/A | |
Depreciation and Amortization Expense | 1.6M +36.66% | 1.2M N/A | |
Total Operating Expenses | 127.2M +56.79% | 81.1M N/A | |
Operating Profit | -71.7M +58.41% | -45.3M N/A | |
Interest Income | 10.9M +179.66% | 3.9M N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 10.9M +179.66% | 3.9M N/A | |
Total Nonoperating Income and Expense | -1.5M -84.02% | -9.5M N/A | |
Income before Taxes | -71.7M +58.41% | -45.3M N/A | |
Income Taxes | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -73.2M +33.68% | -54.8M N/A | |
Net Income from Continuing Operations Applicable to Common | -73.2M +33.68% | -54.8M N/A | |
Basic EPS and Net Income | -1.81 -78.95% | -8.60 N/A | |
Diluted EPS and Net Income | -1.81 -78.95% | -8.60 N/A | |
Basic Weighted Average Shares | 40.5M +536.74% | 6.4M N/A | |
Diluted Weighted Average Shares | 40.5M +536.74% | 6.4M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 31.6M +3.76% | 30.4M N/A | |
Short-Term Investments | 187.5M +156.41% | 73.1M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 219.1M +111.56% | 103.6M N/A | |
Total Current Assets | 267.9M +101.55% | 132.9M N/A | |
Accumulated Depreciation | 5.8M +9.56% | 5.3M N/A | |
Property and Plant and Equipment and Net | 8.6M +80.07% | 4.8M N/A | |
Total Long-Term Assets | 180,000 +20.00% | 150,000 N/A | |
Total Assets | 328.7M +119.68% | 149.6M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 100,000 0.00% | 100,000 N/A | |
Total Current Liabilities | 30.9M +46.23% | 21.1M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 1.5M -97.05% | 52.5M N/A | |
Total Liabilities | 41.1M -44.14% | 73.6M N/A | |
Retained Earnings | -369.9M +24.67% | -296.7M N/A | |
Total Stockholders Equity | 287.6M +217.22% | -245.4M N/A | |
Total Shares Outstanding | 44.4M +1,409.34% | 2.9M N/A | |
Cash Flow | |||
Cash from Operating Activities | -50.9M +5.49% | -48.3M N/A | |
Capital Expenditures | 5.3M +56.02% | 3.4M N/A | |
Cash from Investing Activities | -162.8M +4,583.69% | -3.5M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 214.9M +286.36% | 55.6M N/A | |
Financials Ratio | |||
Gross Margin | 55.40% N/A | N/A N/A | |
Operating Margin | -71.50% N/A | N/A N/A | |
Return on Assets | -30.60% N/A | N/A N/A | |
Return on Equity | -346.51% N/A | N/A N/A | |
Revenue Growth | 53.94% N/A | N/A N/A | |
Current Ratio | 8.66 N/A | N/A N/A | |
Cash Ratio | 1.02 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow